Last updated: 2026-09-08 09:30:01. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
NeOnc Technologies Holdings, Inc. (NTHI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.68, with a market capitalization of $130.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.01 to $12.99. This page covers its latest market performance, valuation, price trends and company information.
$130.46M | |
$5.03 | |
$25.00 | |
$3.01 | |
-- | |
26.00 | |
158.79K | |
-- | |
$12.99 | |
$3.01 | |
-- | |
-- |
NeOnc Technologies Holdings, Inc. (NTHI) is trading at $4.95 in pre-market trading as of 2026-09-08 08:57:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing NTHI before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, NeOnc Technologies Holdings, Inc. (NTHI) moved from $4.61 to $4.68, representing a gain of 1.56% ($0.07).
The stock traded between $4.47 and $5.20 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 124.17 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 16.7%
NTHI is currently trading at $4.68, placing it 16.7% of the way from its 52-week low of $3.01 to its 52-week high of $12.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeOnc Technologies Holdings, Inc. (NTHI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.